Literature DB >> 9849616

Chimeras of human lysozyme and alpha-lactalbumin: an interesting tool for studying partially folded states during protein folding.

H Van Dael1.   

Abstract

Protein folding is an extremely active field of research where biology, chemistry, computer science and physics meet. Although the study of protein-folding intermediates in general and equilibrium intermediates in particular has grown considerably in recent years, many questions regarding the conformational state and the structural features of the various partially folded intermediate states remain unanswered. Performing kinetic measurements on proteins that have had their structures modified by site-directed mutagenesis, the so-called protein-engineering method, is an obvious way to gain fine structural information. In the present review, this method has been applied to a variety of proteins belonging to the lysozyme/alpha-lactalbumin family. Besides recombinants obtained by point mutations of individual critical residues, chimeric proteins in which whole structural elements (10-25 residues) from alpha-lactalbumin were inserted into a human lysozyme matrix are examined. The conformational properties of the equilibrium intermediate states are discussed together with the structural characterization of the partially unfolded states encountered in the kinetic folding pathway.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9849616     DOI: 10.1007/s000180050249

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  2 in total

1.  Equilibrium and kinetic studies on folding of canine milk lysozyme.

Authors:  Herman Van Dael; Petra Haezebrouck; Marcel Joniau
Journal:  Protein Sci       Date:  2003-03       Impact factor: 6.725

2.  Interaction of nano-TiO2 with lysozyme: insights into the enzyme toxicity of nanosized particles.

Authors:  Zhen Xu; Xi-Wei Liu; Yin-Sheng Ma; Hong-Wen Gao
Journal:  Environ Sci Pollut Res Int       Date:  2009-04-24       Impact factor: 4.223

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.